MedPath

Mesoblast Ltd.

Mesoblast Ltd. logo
🇦🇺Australia
Ownership
Public
Established
2004-01-01
Employees
73
Market Cap
-
Website
http://www.mesoblast.com

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

Phase 3
Recruiting
Conditions
Degenerative Disc Disease
Interventions
First Posted Date
2024-03-22
Last Posted Date
2025-04-18
Lead Sponsor
Mesoblast, Ltd.
Target Recruit Count
300
Registration Number
NCT06325566
Locations
🇺🇸

Boomerang Health Care, Concord, California, United States

🇺🇸

Colorado Spine Partners/The Denver Spine and Pain Institute, Greenwood, Colorado, United States

🇺🇸

Eximia EquiHealth Research LLC, Durham, North Carolina, United States

and more 19 locations

Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain

Phase 3
Completed
Conditions
Degenerative Disc Disease
Interventions
First Posted Date
2015-04-09
Last Posted Date
2022-10-19
Lead Sponsor
Mesoblast, Ltd.
Target Recruit Count
404
Registration Number
NCT02412735
Locations
🇺🇸

Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States

🇺🇸

Tennessee Valley Pain Consultants, Huntsville, Alabama, United States

🇺🇸

Arizona Pain Specialists, Scottsdale, Arizona, United States

and more 45 locations

P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies

Phase 3
Completed
Conditions
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin's Lymphoma
Hodgkin's Disease
Interventions
Biological: Infusion of one MPC expanded cord unit and one unexpanded cord unit
Biological: Infusion of two unexpanded cord blood units.
First Posted Date
2013-05-15
Last Posted Date
2020-06-26
Lead Sponsor
Mesoblast, Ltd.
Target Recruit Count
49
Registration Number
NCT01854567
Locations
🇺🇸

University of Miami Health System Sylvester Comprehensive Cancer Center, Miami, Florida, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 6 locations

A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor

Phase 2
Completed
Conditions
Rheumatoid Arthritis
Interventions
First Posted Date
2013-05-10
Last Posted Date
2020-06-26
Lead Sponsor
Mesoblast, Ltd.
Target Recruit Count
48
Registration Number
NCT01851070
Locations
🇺🇸

Pinnacle Research Group, Anniston, Alabama, United States

🇺🇸

Arthrocare Arthritis Care and Research PC, Gilbert, Arizona, United States

🇺🇸

Triwest Research Associates, El Cajon, California, United States

and more 20 locations

Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy

Phase 1
Completed
Conditions
Diabetic Nephropathy
Type 2 Diabetes
Interventions
Biological: Mesenchymal Precursor Cells (MPCs)
First Posted Date
2013-04-30
Last Posted Date
2016-10-14
Lead Sponsor
Mesoblast, Ltd.
Target Recruit Count
30
Registration Number
NCT01843387
Locations
🇦🇺

Monash Universtiy, Clayton, Australia

🇦🇺

Melbourne Renal Research Group, Melbourne, Australia

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Phase 1
Completed
Conditions
Type 2 Diabetes
Interventions
First Posted Date
2012-04-12
Last Posted Date
2020-06-02
Lead Sponsor
Mesoblast, Ltd.
Target Recruit Count
61
Registration Number
NCT01576328
Locations
🇺🇸

SC Clinical Research, Garden Grove, California, United States

🇺🇸

Diabetes Research Institute, Miami, Florida, United States

🇺🇸

Compass Research, Orlando, Florida, United States

and more 15 locations

Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain

Phase 2
Completed
Conditions
Degenerative Disc Disease
Interventions
Biological: Single Dose MPCs Injection
Procedure: Single injection of saline solution
Procedure: Single injection of hyaluronic acid
First Posted Date
2011-02-07
Last Posted Date
2020-06-26
Lead Sponsor
Mesoblast, Ltd.
Target Recruit Count
100
Registration Number
NCT01290367
Locations
🇺🇸

Arizona Pain Specialists, Scottsdale, Arizona, United States

🇺🇸

UC Davis Spine Center, Sacramento, California, United States

🇺🇸

The Spine Institute, Santa Monica, California, United States

and more 11 locations

Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and Fusion

Phase 1
Completed
Conditions
Spinal Stenosis
Cervical Degenerative Disc Disease
Degenerative Spondylolisthesis
Interventions
Biological: NeoFuse
Device: MasterGraft Granules
First Posted Date
2010-04-19
Last Posted Date
2020-06-29
Lead Sponsor
Mesoblast, Ltd.
Target Recruit Count
12
Registration Number
NCT01106417
Locations
🇦🇺

Monash Medical Centre, Clayton, Victoria, Australia

🇦🇺

Royal Melbourne Hospital, Melbourne, Victoria, Australia

Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy

Phase 2
Completed
Conditions
Spinal Stenosis
Degenerative Spondylolisthesis
Cervical Degenerative Disc Disease
Interventions
Procedure: Allograft
Biological: NeoFuse
First Posted Date
2010-04-01
Last Posted Date
2019-08-16
Lead Sponsor
Mesoblast, Ltd.
Target Recruit Count
24
Registration Number
NCT01097486
Locations
🇺🇸

UC Davis Spine Center, Sacramento, California, United States

🇺🇸

The Spine Institute, Santa Monica, California, United States

🇺🇸

Denver Spine, Denver, Colorado, United States

and more 5 locations

Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction

Phase 1
Completed
Conditions
Anterior Cruciate Ligament Injury
Osteoarthritis
Interventions
Biological: MSB-CAR001 Combined With Hyaluronan
First Posted Date
2010-03-17
Last Posted Date
2018-08-15
Lead Sponsor
Mesoblast, Ltd.
Target Recruit Count
17
Registration Number
NCT01088191
Locations
🇦🇺

Emeritus Research, Malvern East, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath